RTSL (Rapid Therapeutic Science Laboratories) EBITDA Margin %: 0.00% (As of Jun. 2023)


What is Rapid Therapeutic Science Laboratories EBITDA Margin %?

Rapid Therapeutic Science Laboratories RTSL EBITDA Margin % is 0.00% as of Jun. 2023.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Rapid Therapeutic Science Laboratories's EBITDA for the three months ended in Jun. 2023 was $0.16 Mil. Rapid Therapeutic Science Laboratories's Revenue for the three months ended in Jun. 2023 was $0.00 Mil. Therefore, Rapid Therapeutic Science Laboratories's EBITDA margin for the quarter that ended in Jun. 2023 was 0.00%.

Rapid Therapeutic Science Laboratories  (OTCPK:RTSL) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Rapid Therapeutic Science Laboratories EBITDA Margin % Related Terms

Rapid Therapeutic Science Laboratories EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Rapid Therapeutic Science Laboratories's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rapid Therapeutic Science Laboratories EBITDA Margin % Chart

Rapid Therapeutic Science Laboratories Annual Data
Trend Mar13 Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Dec21 Dec22
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -4,400.00 -150,900.00 0.00

Rapid Therapeutic Science Laboratories Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

RTSL vs VRAYQ, NNMX, ABT: EBITDA Margin % Comparison

For the Shell Companies subindustry, Rapid Therapeutic Science Laboratories's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rapid Therapeutic Science Laboratories EBITDA Margin % vs Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Rapid Therapeutic Science Laboratories's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Rapid Therapeutic Science Laboratories's EBITDA Margin % falls into.


Rapid Therapeutic Science Laboratories EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Rapid Therapeutic Science Laboratories's EBITDA Margin % for the fiscal year that ended in Dec. 2022 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=0.125/0
= %

Rapid Therapeutic Science Laboratories's EBITDA Margin % for the quarter that ended in Jun. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2023 )/Revenue (Q: Jun. 2023 )
=0.156/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Rapid Therapeutic Science Laboratories (RTSL) has a EBITDA Margin % of 0.00% as of Jun. 2023. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Rapid Therapeutic Science Laboratories and its competitors.
Is Rapid Therapeutic Science Laboratories' EBITDA Margin % too high?
Rapid Therapeutic Science Laboratories' current EBITDA Margin % is 0.00%.
How does Rapid Therapeutic Science Laboratories' EBITDA Margin % compare to VRAYQ and NNMX?
Rapid Therapeutic Science Laboratories' EBITDA Margin % of 0.00% can be compared against companies in the Diversified Financial Services industry. The industry median EBITDA Margin % is 11.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Diversified Financial Services company?
The median EBITDA Margin % among Diversified Financial Services companies is 11.75, based on 93 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Rapid Therapeutic Science Laboratories and its competitors. For the Diversified Financial Services industry, the median EBITDA Margin % is 11.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rapid Therapeutic Science Laboratories's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapid Therapeutic Science Laboratories stock overvalued right now?
Rapid Therapeutic Science Laboratories (RTSL) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Rapid Therapeutic Science Laboratories (RTSL), the current EBITDA Margin % is 0.00% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rapid Therapeutic Science Laboratories Business Description

Address 558 County Road 472, De Leon, TX, USA, 76444
Rapid Therapeutic Science Laboratories Inc currently has no operations and operates as a blank check company.